Volume Alert - AGIO 94.60 Agios Pharmaceuticals Inc $AGIO

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 1:04 PM

Volume Alert - AGIO 94.60 Agios Pharmaceuticals Inc $AGIO Hit a high today of 95.18 Closing the day 10:30 at 94.60 +10.79 +12.87% With a day low of 83.68 and a total volume of 1,790,245.

AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 8 mins ago

CLUB: 6.06 (+0.51), LEJU: 12.23 (-1.93), ANV: 1.77 (-0.27), SSI: 18.62 (+2.88), ROX: 1.53 (-0.25), CLF: 8.75 (-1.46), BIND: 8.57 (-1.98), NADL: 3.29 (-0.68), CSTM: 17.01 (-3.96), VRML: 1.48 (+0.11), WTT: 2.63 (-0.28), CANF: 3.95 (+0.95), DL: 17.98 (+3.01), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.45 (-5.16), ATLC: 2.64 (+0.33), AGIO: 95.61 (+11.80), BBLU: 1.09 (-0.10), OPLK: 24.18 (+2.93)

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'
at The Street - 1 hr 42 mins ago
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)

Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - Wed Nov 19, 8:11AM CST
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.90 (+1.14), LEJU: 12.23 (-1.93), TSLA: 248.07 (-9.63), FCAU: 12.29 (-0.52), LITB: 7.93 (+0.29), TTM: 46.58 (-0.58), DL: 17.98 (+3.01), VA: 36.13 (-0.92), TGT: 72.45 (+4.94), GM: 32.20 (-0.07), AGIO: 95.61 (+11.80), LOW: 62.37 (+3.84), HMC: 31.17 (-0.48), EJ: 8.67 (-0.86), PETM: 77.21 (+3.59)

Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:01AM CST

AGIO: 95.61 (+11.80)

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 95.61 (+11.80)

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.06 (unch), SIX: 40.07 (-0.73), AGIO: 95.61 (+11.80)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.23 (-2.33), OREX: 5.72 (+0.10), PCMI: 8.95 (+0.16), CYAN: 7.35 (-0.49), ACHN: 13.19 (-0.12), TGTX: 14.70 (-0.07), AGIO: 95.61 (+11.80), LIOX: 5.02 (-0.12), SAJA: 5.75 (-0.22), PLNR: 7.20 (-0.19)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 172.16 (+0.78), SLXP: 106.16 (+0.77), ICPT: 156.71 (-5.79), IBB: 296.33 (+1.08), AGIO: 95.61 (+11.80)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 95.61 (+11.80)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.57 (unch), ANET: 76.88 (+0.08), TKMR: 16.45 (+0.08), ORBC: 6.39 (+0.05), MDRX: 12.08 (-0.12), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.88 (-1.03), UBNT: 29.57 (-0.02), RIG: 25.35 (-0.50), KGC: 2.90 (-0.06), APT: 2.83 (+0.10), ANF: 29.11 (+0.17), MITK: 3.91 (-0.05), ZNGA: 2.70 (-0.01), CNET: 1.82 (-0.04), KING: 15.97 (-0.13), NETE: 1.34 (-0.01), SLXP: 106.16 (+0.77), RPRX: 9.14 (-0.05), NADL: 3.31 (-0.66), PGNX: 6.51 (-0.03), AVNR: 13.90 (+0.20), FSLR: 48.67 (-0.79), DVA: 74.79 (-0.44), NDLS: 22.48 (-0.17), ICPT: 156.71 (-5.79), AGIO: 95.61 (+11.80), PLNR: 7.20 (-0.19)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 95.61 (+11.80)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 95.61 (+11.80)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 95.61 (+11.80)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.65 (-0.23), ERF: 15.08 (-0.07), LXP: 10.84 (-0.13), PGEM: 12.34 (-0.09), CCOI: 35.13 (-0.02), TTI: 8.02 (-0.14), SJI: 56.49 (-0.06), NXST: 46.51 (-0.89), VSAT: 65.75 (+0.21), MT: 12.26 (-0.19), LXU: 33.93 (+0.20), HUM: 136.84 (-2.45), PGNX: 6.51 (-0.03), MHR: 4.64 (+0.02), CTB: 32.60 (+0.08), IDRA: 2.55 (+0.07), ISIS: 50.60 (+0.89), BPL: 81.60 (+0.20), SSP: 19.55 (-0.09), AGIO: 95.61 (+11.80), EBIX: 15.99 (-0.24)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 85.02 (-3.78), RNA: 11.51 (+0.01), AGIO: 95.61 (+11.80), CELG: 107.54 (+0.76)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 95.61 (+11.80)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.86 (-0.52), LNKD: 220.27 (-0.80), HAL: 48.06 (-0.48), AGIO: 95.61 (+11.80), IMPV: 41.97 (-0.56)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.09 (-1.62), CLVS: 49.01 (-4.77), ARWR: 5.87 (-0.08), ACHN: 13.19 (-0.12), MRK: 59.55 (-0.34), RTRX: 8.48 (-0.55), RGLS: 16.83 (-1.29), EPZM: 22.91 (-0.52), AGIO: 95.51 (+11.70), RMTI: 10.09 (-0.19), ARNA: 4.15 (-0.16), KERX: 15.35 (-0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ImmunoForge Sets Sights on BIO-Europe 2026 for New Deals

Making Waves with Cutting-Edge Drug Platforms Ah, how time flies in the biotech universe. Here we are, with ImmunoForge prepping to flaunt its high-tech gear at the big show in Cologne: BIO-Europe 2026. The company's aiming to gauge attention with its flashy ELP and LMT platforms, primed and ready for strategic partnerships. ELP: Revolutionizing Drug Delivery You've got...

Victor Care Networks Explores Transformative Mental Health

Connections at the Core of Care Victor Care Network is stepping into the spotlight with a feature on "All Access hosted by Andy Garcia," putting human relationships front and center in mental health support. This ain't just another run-of-the-mill initiative—it’s a deep dive into the bonds that help people when the chips are down. So, what's it all about? Helping...

Allooloo's AI Zones Transform Financial Services Agent

The Allure of AI Agents in Finance Ah, it's a brave new world, my friend. A hundred years ago, the financial services industry relied on flesh-and-blood analysts armed with pens and filing cabinets. Today? It's all about AI agents, and Allooloo Technologies Corp. is at the heart of the action. Just recently, they rolled out specialized zones of record for AI—datasets...

Honeywell Aerospace Faces Investor Class Action Lawsuit

Smoke and Mirrors: Honeywell's Legal Trouble Okay, here's a fun way to start your day: talking lawsuits. Honeywell Aerospace Inc. (NASDAQ:HONA), a name you'd know if you're into aircraft components and avionics, is in hot water. It seems they've been less than transparent about their business prospects, prompting a class action lawsuit from open market purchasers during a...

Harbour BioMed's Batoclimab Injected Into Myasthenia Market

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Amber Intl Unveils AGM Outcomes, Strategic Moves

Diving Into Amber International's AGM Decisions Ah, the hum of shareholder meetings—a fancy little dance of approvals and resolutions! That's exactly what went down on October 23, 2026, for Amber International Holding Limited. A fresh roster, some hefty share awards, and strategic decisions wrapped up their recent annual gathering. Shed the lawyer-speak and let's get...

Graybar's Integrity Shines: Forbes Honors Trust Again

Trust Is Graybar's Secret Sauce Graybar's been hauling the trust trophy back home from Forbes for the second year straight. This ain't just another fleeting accolade—the kind you hang on the office wall without meaning it. What's brewing here is more profound, nestled in the heart of St. Louis and bubbling through its logistics veins. Being named one of Forbes' 2027...

Oakworth Capital's Strategic Gains: A Deep Dive

Oakworth Capital's Big Moves This Quarter Diving right into the Alabama-based Oakworth Capital's latest numbers, they did not pull any punches with a hefty 19% bump in net income. Now, in a world where banking can sometimes feel like riding a porcupine, Oakworth's ability to rise above speaks volumes. They clocked in at $17.2 million net income for the year-to-date period...

Cole Haan Opens 600th Store, Makes Boston Comeback

A Milestone and a Homecoming Who would've thought? Cole Haan, the American staple that seems to draw from an old-world charm and modern flair, is making waves again. They've just hit their 600th store mark—a number not to scoff at, especially when retail's felt the squeeze lately. But it’s not just about another number. It’s about a return, a resounding "we still...

Sivers Semiconductors Shakes Up Auditors and Incentives

Rethinking the Auditing Game Well, what do you know? Sivers Semiconductors just gave the boot to Deloitte AB. Looks like they're rolling out the welcome mat for Ernst & Young AB to scrutinize their books instead. The move, coming hot from the Extraordinary General Meeting, shows they're not messing around with their financial oversight. Maybe it's a bid for fresh...